ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

Abraham, Neena S; Hlatky, Mark A; Antman, Elliott M; Bhatt, Deepak L; Bjorkman, David J; Clark, Craig B; Furberg, Curt D; Johnson, David A; Kahi, Charles J; Laine, Loren; Mahaffey, Kenneth W; Quigley, Eamonn M; Scheiman, James; Sperling, Laurence S; Tomaselli, Gordon F
December 2010
American Journal of Gastroenterology;Dec2010, Vol. 105 Issue 12, p2533
Academic Journal
The article discusses the use of proton pump inhibitors (PPI) and thienopyridines as an alternative treatment for cardiovascular (CV) diseases. It says that clopidogrel is more effective than aspirin in reducing main CV events. It mentions the greater risk for gastrointestinal (GI) bleeding in using clopidogrel and aspirin. It adds that the use of PPI lessens the risk of upper GI bleeding compared with no therapy. It suggests the regular use of PPI to reduce the platelet impacts of clopidogrel.


Related Articles

  • Proton Pump Inhibitors and the Prevention of Recurrent GI Bleed in Patients Treated with Clopidogrel. Oyetayo, O.O.; Farris, C.A.; Wahawisan, J. // Clinical Medicine Insights: Therapeutics;2012, Issue 4, p9 

    Clopidogrel is an antiplatelet agent indicated in the management of atherothrombotic conditions. Bleeding is a predictable adverse event associated with antiplatelet agents. While non-ulcerogenic; a major site of bleeding with clopidogrel is the gastrointestinal (GI) tract. The risk of GI...

  • Clopidogrel plus proton pump inhibitor linked with increased risk for rehospitalization.  // Hem/Onc Today;5/25/2010, Vol. 11 Issue 10, p8 

    The article discusses the study about the impact of taking clopidrogel combined with proton pump inhibitor on risk for rehospitalization following a myocardial infarction or stent placement by researchers from Irvine, California and Seattle.

  • Omeprazole and Clopidogrel -- Is There a Clinically Meaningful Interaction? Boyle, Andrew J. // Clinical Cardiology Alert;Jan2011, Vol. 30 Issue 1, p4 

    No abstract available.

  • The aspirin question.  // Consumer Reports on Health;Jun2013, Vol. 25 Issue 6, p6 

    The article reports on the prevalence of heart attacks and strokes among U.S. consumers and discusses the role that a low dose aspirin regimen can play in preventing heart attacks and strokes. A discussion of medical complications which can be associated with aspirin, and of aspirin alternatives...

  • Management of nonvariceal upper gastrointestinal bleeding. Wee, E. // Journal of Postgraduate Medicine;Apr-Jun2011, Vol. 57 Issue 2, p161 

    Nonvariceal upper gastrointestinal bleeding is unique from variceal bleeding in terms of patient characteristics, management, rebleeding rates, and prognosis, and should be managed differently. The majority of nonvariceal upper gastrointestinal bleeds will not rebleed once treated successfully....

  • PPIs and Clopidogrel: Do We Have to Worry? Kuritzky, Louis // OB/GYN Clinical Alert;Dec2009, Vol. 26 Issue 8, p23 

    The article reports on the pharmacological relation between proton pump inhibitor (PPI) and clopidogrel in the U.S. It mentions that the antiplatelet effect of clopidogrel depends on its conversion and activation through the 2C19 pathway of the P450 system where the blockade of this pathway...

  • Clinical: Journals Watch - Ligament damage and sunbeds. Croton, Lizzie // GP: General Practitioner;4/2/2010, p22 

    The article offers information on several studies conducted related to treatment of several health problems. It states that a study revealed the treatment of anterior cruciate injuries with the help of clopidogrel and proton pump inhibitors (PPI). It mentions the study that revealed the...

  • The Evidence Base of Proton Pump Inhibitor Chemopreventative Agents in Barrett's Esophagus–The Good, The Bad, and The Flawed! Leedham, Simon; Jankowski, Janusz // American Journal of Gastroenterology;Jan2007, Vol. 102 Issue 1, p21 

    Gastric acid is believed to be an important etiological factor in the pathogenesis of Barrett's esophagus. Pulsatile acid exposure increases cell proliferation in ex vivo Barrrett's tissue and normalization of esophageal pH reverses this. Proton pump inhibitors (PPIs) are the mainstay of therapy...

  • Potential Interaction between Clopidogrel and Proton Pump Inhibitors. Howard, Patricia A.; Vacek, James L. // American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 6, p353 

    Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation. The antiplatelet action of clopidogrel is felt to be of critical importance for the reduction of abrupt thrombotic occlusion of stents, particularly with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics